499 related articles for article (PubMed ID: 38236598)
1. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
[TBL] [Abstract][Full Text] [Related]
2. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
4. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
[TBL] [Abstract][Full Text] [Related]
6. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
9. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
10. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K
JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
14. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
15. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Hata H; Matsumura C; Chisaki Y; Nishioka K; Tokuda M; Miyagi K; Suizu T; Yano Y
Cancer Control; 2022; 29():10732748221130576. PubMed ID: 36254804
[TBL] [Abstract][Full Text] [Related]
17. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
19. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
20. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
